Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$2.60
-4.1%
$3.26
$2.11
$12.60
$5.13M-0.03526,747 shs508,854 shs
Briacell Therap stock logo
BCTX
Briacell Therap
$0.77
-61.9%
$3.03
$0.69
$29.40
$13.69M1.27723,185 shs23.56 million shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.66
+7.8%
$1.27
$0.62
$5.01
$26.06M1.722.31 million shs2.84 million shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.42
+0.6%
$3.34
$2.57
$6.88
$21.01M0.629,082 shs2,261 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-4.06%-0.38%-17.46%-33.33%-62.97%
Briacell Therap stock logo
BCTX
Briacell Therap
-61.88%-73.54%-75.32%-82.81%-94.48%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
+7.79%+46.90%+37.19%+55.14%+124.32%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+0.59%+3.01%-1.13%+24.36%-39.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.3398 of 5 stars
0.02.00.04.33.21.70.0
Briacell Therap stock logo
BCTX
Briacell Therap
1.8759 of 5 stars
3.52.00.00.02.40.00.6
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
2.4312 of 5 stars
3.73.00.00.02.70.00.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.4581 of 5 stars
0.04.00.00.03.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
0.00
N/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
3.00
Buy$32.004,055.84% Upside
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.33
Buy$14.00743.37% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ALBT, MIRA, NAII, and BCTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2025
Briacell Therap stock logo
BCTX
Briacell Therap
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
$1.33M3.69N/AN/A($11.37) per share-0.23
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A($2.20) per shareN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.13 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
-$7.90M-$19.96N/AN/A-647.29%N/A-50.13%8/18/2025 (Estimated)
Briacell Therap stock logo
BCTX
Briacell Therap
-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/25/2025 (Estimated)

Latest ALBT, MIRA, NAII, and BCTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.10N/AN/AN/AN/AN/A
6/13/2025Q3 2025
Briacell Therap stock logo
BCTX
Briacell Therap
-$1.76-$1.64+$0.12-$1.64N/AN/A
5/14/2025Q1 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.15-$0.11+$0.04-$0.11N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/13/2025Q1 2025
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A-$1.43N/A-$1.43N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/AN/AN/AN/AN/A
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
N/A
0.19
0.19
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
3.41
3.41
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
12.86
12.86
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35

Institutional Ownership

CompanyInstitutional Ownership
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
1.42%
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalon GloboCare Corp. stock logo
ALBT
Avalon GloboCare
51.89 million1.19 millionNot Optionable
Briacell Therap stock logo
BCTX
Briacell Therap
86.78 million6.39 millionOptionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
216.92 million15.80 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
CarnoSyn Brands announces new U.S. distribution pact with B&D Nutritional
(NAII) Trading Advice

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalon GloboCare stock logo

Avalon GloboCare NASDAQ:ALBT

$2.60 -0.11 (-4.06%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$2.50 -0.10 (-3.85%)
As of 07:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$0.77 -1.25 (-61.88%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$0.83 +0.06 (+8.18%)
As of 07:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.66 +0.12 (+7.79%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$1.69 +0.03 (+1.81%)
As of 07:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.46 +0.06 (+1.79%)
As of 07/15/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.